Over the past 3 years we have performed 10 haploidentical peripheral blood stem cell transplants in patients with incurable haematological malignancies and no prospect of a matched unrelated donor within an adequate time period. Conditioning consisted of ATG, TBI, thiotepa, cyclophosphamide and additional radioimmunotherapy in five patients. All patients received G-CSF mobilized peripheral blood stem cell grafts. GVHD prophylaxis consisted of T cell depletion by CD34 ؉ selection; no post-transplant immunosuppression was given in nine patients. Stable engraftment was achieved in nine patients; one case of acute graft rejection was observed. Seven patients developed grade I acute GVHD, and six patients have developed chronic GVHD. Infections were the most significant clinical problem post transplant. Two patients have suffered a relapse of their disease and two further patients have died of transplant-related complications. After a median follow-up of 13 months (range 5-37 months) six patients are surviving in remission. We conclude that haploidentical PBSCT is a reasonable alternative to a MUD transplant. Bone Marrow Transplantation (2000) 25, Suppl. 2, S9-S11.
Allogeneic stem cell transplantation remains the only curative treatment option for many patients with haematological malignancies. The broader application of this therapeutic strategy is limited by donor availability. A HLA-compatible family donor is available for only approximately 30% of patients. Thanks to the establishment of large volunteer donor registries a matched unrelated donor can be found for 60-70% of patients within 6 months. 1 However, for patients with rare HLA haplotypes, patients from ethnic Correspondence: Dr D Bunjes, BMT Unit, Department of Internal Medicine III, Ulm University Hospital, Robert-Koch-Strasse 8, 89070 Ulm, Germany minorities and patients with rapidly progressive disease a compatible matched unrelated donor may not be available within an appropriate time frame. For such patients a haploidentical family donor might be an appropriate alternative since a haploidentical donor is available in more than 90% of cases. Exorbitant transplant-related mortality has limited the enthusiasm for the use of this source of stem cells. A high risk of severe graft-versus-host disease was observed after haploidentical bone marrow transplantation with conventional GVHD prophylaxis 2 whereas a high risk of graft failure was associated with the use of T cell-depleted bone marrow grafts. 3 Within the last 5 years the Perugia group has reported two groups of patients who were transplanted with T cell-depleted, G-CSF mobilised peripheral blood stem cells either alone or in combination with T celldepleted bone marrow. 4, 5 The preliminary results have been encouraging but one should bear in mind that the median age of patients in these reports has been 18 years. Here, we report a single centre experience of haploidentical T cell-depleted peripheral blood stem cell transplants in 10 adult patients.
Patients and methods

Patients
From 1996 to 1999 10 patients (seven females, three males) were included in a pilot study at the Adult BMT Unit of Ulm University. Their median age was 37 years, with a range from 22 to 52 years of age. They were suffering from refractory AML (two cases), AML in relapse (two cases), CML in accelerated phase (two cases), CML 1st chronic phase (two cases); CML in 2nd chronic phase (one case) and CML in blast crisis (one case).
Conditioning
The conditioning regimen consisted of ATG (Fresenius) 5 mg/kg day −4 to day −1, TBI 2 × 2 Gy day −7 to day −5, thiotepa 10 mg/kg day −5, cyclophosphamide 60 mg/kg day −3 to day −2. Five patients were treated with additional 
Stem cell mobilization
Donors were treated with G-CSF 2 × 6 g/kg/day for 5-7 days. Between days 4 and 7 of G-CSF treatment, one to three leukaphereses were performed using the COBE Spectra (COBE, Lakewood, CO, USA) cell separator. The pooled aphereses were washed in a COBE 2991 cell washer to remove platelets. 6 Donors and patients were matched for one HLA haplotype and mismatched at two (n = 2) or three loci (n = 8) in the other haplotype. Parents served as donors in two cases, siblings in three cases, children in four cases and an aunt in one case.
GVHD prophylaxis
GVHD prophylaxis was performed by CD34
+ selection. With the exception of the first patient no post-transplant immunosuppression was given. For CD34 + selection either the CeprateSC (three patients) (CellPro Deutschland, München, Germany) or the CliniMACS (seven patients) (Miltenyi Biotec, Bergisch Gladbach, Germany) device was used with (n = 2) or without (n = 8) a further immunomagnetic CD3 depletion using the VarioMACS system (Miltenyi).
Supportive care
All patients were treated prophylactically with ofloxacin, fluconazole, acyclovir and cotrimoxazol. The last five patients were treated with prophylactic gancyclovir (5 mg/kg/day i.v.) from day +7 to day +21. Prophylaxis with acyclovir, fluconazole and cotrimoxazol was maintained until the last five patients in the series had achieved Ͼ200 CD4 + T cells/l. All patients were treated with G-CSF 5 g/kg from day +7.
Results
Graft composition
The peripheral blood stem cell grafts contained a median of 
Engraftment
Nine out of 10 patients achieved stable haemopoietic engraftment, one case of acute graft rejection was observed. The median time to achieve Ͼ500 neutrophils/l was 10 days (range 10-15 days), the median time to Ͼ20 000 thrombocytes/l was 14 days (range 11-26 days).
GVHD
Seven out of nine evaluable patients developed mild grade I acute GVHD, two remained free of acute GVHD. Six out of nine evaluable patients developed mild, extensive chronic GVHD.
Infectious complications
All six CMV-seropositive patients developed moderate to high-grade CMV viraemia. CMV disease was observed in five patients (CMV IP four patients, CMV hepatitis one patient). Other infectious complications include one case of cerebral aspergillosis, one case of cerebral toxoplasmosis and three cases of chronic bacterial sinusitis.
Relapse
Two patients have suffered a relapse of their leukaemia, one patient with CML blast crisis and one patient with CML in accelerated phase.
Transplant-related mortality and causes of death
Two patients have died of transplant-related complications, one patient of CMV IP plus cerebral aspergillosis and one patient of a pneumonia of unknown origin. Two further patients relapsed and died.
Survival and disease-free survival
After a median follow-up period of 12 months (range 4-36 months) six out of the 10 patients are surviving diseasefree; all surviving CML patients are in molecular remission.
Discussion
Although haploidentical family donors are available for Ͼ90% of patients with haematological malignancies the experience with this source of stem cells is limited. In the past transplant-related mortality after such a procedure was prohibitive due to a high incidence of graft failure and severe GVHD. 2, 3, 7, 8 In the last 5 years two groups have reported more encouraging results. 4, 5, 9 These improved results have been achieved by intensifying the conditioning regimen, rigorous T cell depletion and the use of grafts with a high stem cell dose. 10 It should be remembered, however, that both series of patients contained a significant proportion of children with median ages of 18 and 16 years, respectively. 5, 9 Here, we report our experience with an entirely adult group of patients essentially treated according to the original Perugia protocol. 4 Stable engraftment was achieved in 90% of patients in spite of the fact that the stem cell dose was not as high as originally intended, presumably because the majority of donors were children donating for parents. The incidence of graft failure was similar to the Perugia experience 5 although patients received fractionated total body irradiation and not single-dose, high-dose rate irradiation. 4 In contrast to the Perugia group, we observed a significant incidence of both acute and chronic GVHD. 5 This higher incidence of GVHD is presumably related to two factors: the older age of our patients and the less rigorous T cell depletion. Age is a major risk factor for GVHD 11 and there is a clear correlation between the number of T CD34 selection in mismatched transplantation D Bunjes et al S11 cells infused and the risk of GVHD in patients receiving T cell-depleted grafts. 12 Fortunately, GVHD has been mild and has responded well to immunosuppressive therapy. The major clinical problem observed in our group of patients has been a high incidence of bacterial, fungal and viral infections. This high incidence of infections is probably due to the delayed immune reconstitution observed in these patients. The recovery of CD4 + T cells has been extremely delayed as previously described 5, 13 and since the CD4 + count correlates with the risk of infections a high incidence of infections is to be expected.
14 After a median follow-up period of 13 months six patients are alive and in remission. Four patients have died, two of leukaemic relapse and two patients of infectious complications. A relapse rate of 20% may appear to be significantly lower than in previous reports 5, 9 but this is probably due to patient selection since our group of patients contains a higher proportion of CML patients and fewer cases of refractory acute leukaemia. It is unclear at present whether the intensified conditioning with radioimmunoconjugates in 50% of our patients contributed to the relatively low relapse rate. 15, 16 Our preliminary results suggest that a haploidentical peripheral blood stem cell transplant is an acceptable alternative to a MUD transplant in patients with high risk leukaemias with no prospect of obtaining a matched unrelated donor in an appropriate period of time.
